BDX vs INVA: fair value comparison
Becton, Dickinson and Company and Innoviva, Inc. · Updated 2026-08-31
Both currently screen as fairly valued on TickrTrends' Forward Fair Value model. Within Healthcare, BDX currently sits closer to the top of our discount ranking.
| BDX | INVA | |
|---|---|---|
| Verdict | Fairly valued | Fairly valued |
| Last price | $189.52 | $20.77 |
| 12-month range | $145.33–$201.91 | $18.11–$23.41 |
| Sector rank | #55 of 113 Healthcare | #60 of 113 Healthcare |
| Quality grade | B | B |
| Momentum grade | — | B |
| Leverage | Moderate | Low |
| Margin trend | Expanding | — |
| Revenue growth | Modest | — |
| RSI zone | Overbought | Neutral |
| 50/200-day trend | — | Downtrend |
| DCF cross-check | Undervalued | — |
| 52-week position | The top quarter | The upper-middle quarter |
Full single-stock breakdowns: BDX fair value analysis · INVA fair value analysis